CD274 and neoplasm: In a pembrolizumab trial, the response rate for patients with a PD‐L1 tumor proportion score (TPS) of 50% or higher was 45.2%, compared with 16.5% in patients with a PD‐L1 TPS of 1%–49% and 10.7% in PD‐L1‐negative patients.8